Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + dolutegravir + abacavir
- Development stage
- Approved
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lamivudine + dolutegravir + abacavir is an oral fixed-dose combination antiretroviral regimen for treatment of HIV-1 infection. It combines two nucleoside analogue reverse transcriptase inhibitors, abacavir and lamivudine, with the integrase strand transfer inhibitor dolutegravir. Abacavir and lamivudine inhibit HIV reverse transcriptase and terminate viral DNA chain elongation after intracellular phosphorylation, while dolutegravir blocks HIV integrase strand transfer and prevents integration of viral DNA into the host genome. Marketed as Triumeq and Triumeq PD, this small-molecule combination was developed by ViiV Healthcare and is used in adults and pediatric patients as a complete once-daily regimen; it is not curative but suppresses viral replication and supports immune recovery.
- Brand names
- TriumeqTriumeq PD
- Other names
- lamivudine + dolutegravir + abacavirabacavir + dolutegravir + lamivudinedolutegravir + abacavir + lamivudine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on lamivudine + dolutegravir + abacavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + dolutegravir + abacavir.